Biotech Values

[jaybird249]

OXGN trading under cash value with two Phase 2/3 studies. Another catalyst in a few weeks:

Phase 1b/2 pazopanib/fosbretabulin combo trial: Results from the dose-range portion of this trial being led by The Christie NHS Foundation Trust will be presented at the European Society of Gynaecological Oncology taking place October 24-27. Why is this trial exciting? The belief is that is this could be a very effective combo treatment given that fosbretabulin effectively targets the cancer blood vessels that are newly forming near the center of the cancer while pazopanib targets the more established blood vessels that fosbretabulin doesn't address